Research Explorer

Project

An mRNA replicon based immunotherapeutic combinational treatment for triple negative breast cancer
Code
3S011316
Duration
01 January 2016 → 31 December 2019
Funding
Research Foundation - Flanders (FWO)
Research disciplines
  • Medical and health sciences
    • Immunology
    • Morphological sciences
    • Oncology
    • Immunology
    • Morphological sciences
    • Oncology
    • Biomarker discovery and evaluation
    • Drug discovery and development
    • Medicinal products
    • Pharmaceutics
    • Pharmacognosy and phytochemistry
    • Pharmacology
    • Pharmacotherapy
    • Toxicology and toxinology
    • Other pharmaceutical sciences
    • Immunology
    • Morphological sciences
    • Oncology
Keywords
immunotherapy cancer mRNA therapeutics
 
Project description
 

Our recently developed mRNA replicon platform will be used to develop a novel immunotherapeutic combinatorial treatment for triple-negative breast cancer. The treatment consists of three parts: (1) an mRNA replicon based therapeutic cancer vaccine coding for the universal tumor-associated antigen p62, (2) an mRNA replicon that produces IL-12 under the control of a registered drug, and (3) an anti-PD-L1 immune checkpoint inhibitor